STeP provides Breakthrough-style benefits - interactive review and prioritization - for devices reasonably expected to significantly improve the safety of currently available treatments or diagnostics for non-life-threatening conditions. The program is aimed at devices, and device-led combination products, that fall short of the Breakthrough criteria because the condition is less serious. Participants can use sprint discussions and data development plans, and requests go in through the Q-Submission process.

Why it matters

Often used for safer redesigns of existing devices (e.g., reducing infection risk, eliminating a hazardous material). Acceptance is selective.

Common pitfalls

•A common pitfall is misunderstanding that STeP focuses on safety improvements for non-life-threatening conditions, not efficacy for life-threatening ones. Another mistake is assuming all safety improvements qualify, as the program specifically targets "significant" safety improvements. Manufacturers sometimes fail to provide sufficient justification that their device offers a substantial safety improvement over existing technologies when applying for STeP designation.
•Failing to engage with the FDA early and often, which is a key benefit of the STeP program, can hinder the expedited review process.
•Misinterpreting "non-life-threatening conditions" can lead to inappropriate applications, as the program has specific criteria for this aspect.

Sources

Safer Technologies Program (STeP) · FDA
FDA - Medical Devices · FDA
European Commission - Medical Devices · European Commission

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.